Drugs / Sinibolimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06848920 | Mar 2025 → Jun 2027 expected | differentiated thyroid carcinoma | Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sinibolimab | “This study is a single-arm, prospective Phase II clinical trial designed to evaluate the efficacy and safety of Sinibolimab in combination with Lenvatinib as a neoadjuvant...” NCT06848920 ↗ |
| Action | Inhibit | “Sinibolimab, a PD-1 inhibitor” NCT06848920 ↗ |